These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20020312)

  • 1. Design and methods of a strategic outcome study for chronic kidney disease: Frontier of Renal Outcome Modifications in Japan.
    Yamagata K; Makino H; Akizawa T; Iseki K; Itoh S; Kimura K; Koya D; Narita I; Mitarai T; Miyazaki M; Tsubakihara Y; Watanabe T; Wada T; Sakai O;
    Clin Exp Nephrol; 2010 Apr; 14(2):144-51. PubMed ID: 20020312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Behavior Modification on Outcome in Early- to Moderate-Stage Chronic Kidney Disease: A Cluster-Randomized Trial.
    Yamagata K; Makino H; Iseki K; Ito S; Kimura K; Kusano E; Shibata T; Tomita K; Narita I; Nishino T; Fujigaki Y; Mitarai T; Watanabe T; Wada T; Nakamura T; Matsuo S;
    PLoS One; 2016; 11(3):e0151422. PubMed ID: 26999730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving care coordination between nephrology and primary care: a quality improvement initiative using the renal physicians association toolkit.
    Haley WE; Beckrich AL; Sayre J; McNeil R; Fumo P; Rao VM; Lerma EV
    Am J Kidney Dis; 2015 Jan; 65(1):67-79. PubMed ID: 25183380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan: The Reach-J CKD cohort study.
    Hoshino J; Nagai K; Kai H; Saito C; Ito Y; Asahi K; Kondo M; Iseki K; Iseki C; Okada H; Kashihara N; Narita I; Wada T; Combe C; Pisoni RL; Robinson BM; Yamagata K
    Clin Exp Nephrol; 2018 Apr; 22(2):309-317. PubMed ID: 28741051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pragmatic Randomized, Controlled Trial of Patient Navigators and Enhanced Personal Health Records in CKD.
    Navaneethan SD; Jolly SE; Schold JD; Arrigain S; Nakhoul G; Konig V; Hyland J; Burrucker YK; Dann PD; Tucky BH; Sharp J; Nally JV
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1418-1427. PubMed ID: 28778854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrologists' perspectives on ambulatory care of patients with non-dialysis chronic kidney disease - A qualitative study.
    Haase A; Stracke S; Chenot JF; Weckmann G
    Health Soc Care Community; 2019 Jul; 27(4):e438-e448. PubMed ID: 30945392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Care Physicians' Perceived Barriers to Nephrology Referral and Co-management of Patients with CKD: a Qualitative Study.
    Greer RC; Liu Y; Cavanaugh K; Diamantidis CJ; Estrella MM; Sperati CJ; Soman S; Abdel-Kader K; Agrawal V; Plantinga LC; Schell JO; Simon JF; Vassalotti JA; Jaar BG; Choi MJ;
    J Gen Intern Med; 2019 Jul; 34(7):1228-1235. PubMed ID: 30993634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of superimposed nephrological care to guidelines-directed management by primary care physicians of patients with stable chronic kidney disease: a randomized controlled trial.
    Saudan P; Ponte B; Marangon N; Martinez C; Berchtold L; Jaques D; Ernandez T; de Seigneux S; Carballo S; Perneger T; Martin PY
    BMC Nephrol; 2020 Apr; 21(1):128. PubMed ID: 32272886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing advanced chronic kidney disease: a primary care guide.
    Sakhuja A; Hyland J; Simon JF
    Cleve Clin J Med; 2014 May; 81(5):289-99. PubMed ID: 24789588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study.
    Chang AR; Evans M; Yule C; Bohn L; Young A; Lewis M; Graboski E; Gerdy B; Ehmann W; Brady J; Lawrence L; Antunes N; Green J; Snyder S; Kirchner HL; Grams M; Perkins R
    BMC Nephrol; 2016 Nov; 17(1):168. PubMed ID: 27825313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CKD Outcomes and Practice Patterns Study (CKDopps): Rationale and Methods.
    Mariani L; Stengel B; Combe C; Massy ZA; Reichel H; Fliser D; Pecoits-Filho R; Lopes AA; Yamagata K; Wada T; Wong MM; Speyer E; Port FK; Pisoni RL; Robinson BM
    Am J Kidney Dis; 2016 Sep; 68(3):402-13. PubMed ID: 27113505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effective treatment modalities for reducing morbidity associated with chronic kidney disease.
    Ferguson TW; Tangri N; Rigatto C; Komenda P
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):243-52. PubMed ID: 25661187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and protocol for the Dialysis Optimal Health Program (DOHP) randomised controlled trial.
    Knowles SR; Ski CF; Langham R; O'Flaherty E; Thompson DR; Rossell SL; Moore G; Hsueh YS; Castle DJ
    Trials; 2016 Sep; 17(1):447. PubMed ID: 27612446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial.
    Jiamjariyapon T; Ingsathit A; Pongpirul K; Vipattawat K; Kanchanakorn S; Saetie A; Kanistanon D; Wongprompitak P; Leesmidt V; Watcharasaksilp W; Wang W; Chandraker AK; Tungsanga K
    BMC Nephrol; 2017 Mar; 18(1):83. PubMed ID: 28253839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge deficit of patients with stage 1-4 CKD: a focus group study.
    Lopez-Vargas PA; Tong A; Phoon RK; Chadban SJ; Shen Y; Craig JC
    Nephrology (Carlton); 2014 Apr; 19(4):234-43. PubMed ID: 24428274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceived Health and Quality of Life in Patients With CKD, Including Those With Kidney Failure: Findings From National Surveys in France.
    Legrand K; Speyer E; Stengel B; Frimat L; Ngueyon Sime W; Massy ZA; Fouque D; Laville M; Combe C; Jacquelinet C; Durand AC; Edet S; Gentile S; Briançon S; Ayav C
    Am J Kidney Dis; 2020 Jun; 75(6):868-878. PubMed ID: 31879215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Web-based consultation between general practitioners and nephrologists: a cluster randomized controlled trial.
    van Gelder VA; Scherpbier-de Haan ND; van Berkel S; Akkermans RP; de Grauw IS; Adang EM; Assendelft PJ; de Grauw WJC; Biermans MCJ; Wetzels JFM
    Fam Pract; 2017 Aug; 34(4):430-436. PubMed ID: 28158576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New measures against chronic kidney diseases in Japan since 2018.
    Fukui A; Yokoo T; Nangaku M; Kashihara N
    Clin Exp Nephrol; 2019 Nov; 23(11):1263-1271. PubMed ID: 31502103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study.
    Hasegawa T; Sakamaki K; Koiwa F; Akizawa T; Hishida A;
    Clin Exp Nephrol; 2019 Feb; 23(2):189-198. PubMed ID: 30069609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.